Does the media refer more to SUPN or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 11 mentions for Lantheus and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Lantheus' score of 0.62 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SUPN or AMRX?

In the previous week, Amneal Pharmaceuticals had 9 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 17 mentions for Amneal Pharmaceuticals and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Amneal Pharmaceuticals' score of 0.73 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 6 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LQDA or SUPN?

In the previous week, Supernus Pharmaceuticals had 3 more articles in the media than Liquidia. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 5 mentions for Liquidia. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Liquidia's score of 0.48 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Supernus Pharmaceuticals (SUPN) Competitors

$42.66 -0.63 (-1.46%)

As of 04:00 PM Eastern

Compare

SUPN vs. CRNX, BLTE, LNTH, AMRX, and LQDA

Should you buy Supernus Pharmaceuticals stock or one of its competitors? Supernus Pharmaceuticals's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), and Liquidia (LQDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Supernus Pharmaceuticals' return on equity of 11.13% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Supernus Pharmaceuticals currently has a consensus price target of $62.83, indicating a potential upside of 47.29%. Crinetics Pharmaceuticals has a consensus price target of $83.90, indicating a potential downside of 1.24%. Given Supernus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Supernus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 3 mentions for Crinetics Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Crinetics Pharmaceuticals' score of 0.11 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	2.99	-$38.55M	-$1.92	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Summary

Supernus Pharmaceuticals beats Crinetics Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Belite Bio?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Belite Bio (NASDAQ:BLTE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Supernus Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	2.99	-$38.55M	-$1.92	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A

In the previous week, Supernus Pharmaceuticals had 7 more articles in the media than Belite Bio. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.82 beat Supernus Pharmaceuticals' score of 0.79 indicating that Belite Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Supernus Pharmaceuticals	Positive
Belite Bio	Very Positive

Belite Bio has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Belite Bio	N/A	-11.84%	-11.62%

Supernus Pharmaceuticals has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Supernus Pharmaceuticals currently has a consensus price target of $62.83, suggesting a potential upside of 47.29%. Belite Bio has a consensus price target of $218.73, suggesting a potential upside of 30.72%. Given Supernus Pharmaceuticals' higher possible upside, research analysts plainly believe Supernus Pharmaceuticals is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

0.5% of Belite Bio shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Supernus Pharmaceuticals beats Belite Bio on 9 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Lantheus?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Supernus Pharmaceuticals currently has a consensus target price of $62.83, suggesting a potential upside of 47.29%. Lantheus has a consensus target price of $108.11, suggesting a potential upside of 8.39%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

99.1% of Lantheus shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lantheus has a net margin of 17.69% compared to Supernus Pharmaceuticals' net margin of -13.23%. Lantheus' return on equity of 28.10% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Lantheus	17.69%	28.10%	14.35%

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Lantheus has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	2.99	-$38.55M	-$1.92	N/A
Lantheus	$1.54B	4.22	$233.56M	$4.14	24.09

In the previous week, Lantheus had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 11 mentions for Lantheus and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Lantheus' score of 0.62 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Supernus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Amneal Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Supernus Pharmaceuticals presently has a consensus price target of $62.83, indicating a potential upside of 47.29%. Amneal Pharmaceuticals has a consensus price target of $21.00, indicating a potential upside of 6.22%. Given Supernus Pharmaceuticals' higher possible upside, equities analysts clearly believe Supernus Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 8.5% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

In the previous week, Amneal Pharmaceuticals had 9 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 17 mentions for Amneal Pharmaceuticals and 8 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Amneal Pharmaceuticals' score of 0.73 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	2.99	-$38.55M	-$1.92	N/A
Amneal Pharmaceuticals	$3.02B	2.09	$72.06M	$0.49	40.35

Summary

Amneal Pharmaceuticals beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Liquidia presently has a consensus target price of $98.08, suggesting a potential upside of 43.33%. Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 47.29%. Given Supernus Pharmaceuticals' higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Liquidia has a net margin of 30.74% compared to Supernus Pharmaceuticals' net margin of -13.23%. Liquidia's return on equity of 149.65% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

In the previous week, Supernus Pharmaceuticals had 3 more articles in the media than Liquidia. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 5 mentions for Liquidia. Supernus Pharmaceuticals' average media sentiment score of 0.79 beat Liquidia's score of 0.48 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has higher revenue and earnings than Liquidia. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.69	-$68.92M	$1.37	49.95
Supernus Pharmaceuticals	$830.44M	2.99	-$38.55M	-$1.92	N/A

64.5% of Liquidia shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Summary

Liquidia beats Supernus Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SUPN vs. The Competition

Export

Metric	Supernus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.48B	$12.50B	$7.27B	$13.17B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	-22.22	792.35	274.71	25.79
Price / Sales	2.99	1,000.83	681.64	110.71
Price / Cash	11.59	88.64	77.80	52.76
Price / Book	2.30	10.62	10.46	6.31
Net Income	-$38.55M	$2.81B	$3.49B	$359.77M
7 Day Performance	1.57%	-1.05%	-1.23%	-0.12%
1 Month Performance	-5.95%	-2.93%	-4.48%	-4.01%
1 Year Performance	-9.58%	2.65%	16.46%	6.19%

Supernus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SUPN Supernus Pharmaceuticals	3.6041 of 5 stars	$42.66 -1.5%	$62.83 +47.3%	-8.1%	$2.48B	$830.44M	N/A	778
CRNX Crinetics Pharmaceuticals	1.2231 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210
BLTE Belite Bio	3.7756 of 5 stars	$176.36 +1.7%	$218.73 +24.0%	+142.8%	$7.10B	N/A	N/A	41	Positive News
LNTH Lantheus	3.3194 of 5 stars	$100.23 0.0%	$108.11 +7.9%	+87.3%	$6.54B	$1.54B	24.21	1,193	Positive News
AMRX Amneal Pharmaceuticals	3.1935 of 5 stars	$19.40 -3.8%	$20.14 +3.8%	+104.0%	$6.20B	$3.02B	39.59	8,500	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SUPN) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. CRNX, BLTE, LNTH, AMRX, and LQDA

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

How does Supernus Pharmaceuticals compare to Belite Bio?

Summary

How does Supernus Pharmaceuticals compare to Lantheus?

Summary

How does Supernus Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does Supernus Pharmaceuticals compare to Liquidia?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. CRNX, BLTE, LNTH, AMRX, and LQDA

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Is SUPN or CRNX more profitable?

Do analysts recommend SUPN or CRNX?

Does the media refer more to SUPN or CRNX?

Which has more risk and volatility, SUPN or CRNX?

Do institutionals and insiders have more ownership in SUPN or CRNX?

Which has preferable earnings & valuation, SUPN or CRNX?

Summary

How does Supernus Pharmaceuticals compare to Belite Bio?

Which has better earnings & valuation, SUPN or BLTE?

Does the media refer more to SUPN or BLTE?

Is SUPN or BLTE more profitable?

Which has more volatility and risk, SUPN or BLTE?

Do analysts rate SUPN or BLTE?

Do insiders & institutionals believe in SUPN or BLTE?

Summary

How does Supernus Pharmaceuticals compare to Lantheus?

Do analysts rate SUPN or LNTH?

Do insiders & institutionals hold more shares of SUPN or LNTH?

Is SUPN or LNTH more profitable?

Which has more volatility and risk, SUPN or LNTH?

Which has better valuation & earnings, SUPN or LNTH?

Does the media refer more to SUPN or LNTH?

Summary

How does Supernus Pharmaceuticals compare to Amneal Pharmaceuticals?

Do analysts rate SUPN or AMRX?

Which has more volatility and risk, SUPN or AMRX?

Do institutionals & insiders have more ownership in SUPN or AMRX?

Is SUPN or AMRX more profitable?

Does the media favor SUPN or AMRX?

Which has stronger valuation and earnings, SUPN or AMRX?

Summary

How does Supernus Pharmaceuticals compare to Liquidia?

Do analysts prefer LQDA or SUPN?

Is LQDA or SUPN more profitable?

Does the media prefer LQDA or SUPN?

Which has preferable earnings & valuation, LQDA or SUPN?

Do insiders & institutionals have more ownership in LQDA or SUPN?

Which has more risk and volatility, LQDA or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools